US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Seaport Therapeutics

18.15

+0.24001.34%

Post-market: 18.150.00000.00%19:30 EDT

Volume:171.21K

Turnover:3.11M

Market Cap:971.58M

PE:-7.21

High:18.79

Open:18.00

Low:17.89

Close:17.91

52wk High:28.38

52wk Low:14.85

Shares:53.53M

Float Shares:14.16M

Volume Ratio:0.78

T/O Rate:1.21%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.5160

EPS(LYR):-10.0430

ROE:-28.08%

ROA:-18.90%

PB:2.30

PE(LYR):-1.81

Loading ...

Overview Company News Filings

PureTech-Founded Seaport Therapeutics Unveils Strong Phase 1 Data for GlyphAgo

Seaport Therapeutics Says Drug Potentially Reduces Liver Impact of Depression Treatment

MT Newswires Live

Seaport Therapeutics presents additional PK data from Phase 1 GlyphAgo trial

Seaport Therapeutics Presents Phase 1 GlyphAgo Data Showing 6.8-Fold Increase in Agomelatine Bioavailability

Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of Glyphago™ at the 39TH European College of Neuropsychopharmacology (Ecnp) Congress

THOMSON REUTERS

Seaport Therapeutics Price Target Maintained with a $50.00/Share by HC Wainwright & Co.

PureTech-Founded Seaport Therapeutics Doses First Patient in Mid-Stage GAD Trial of GlyphAgo

Seaport Therapeutics Doses First Patient in Phase 2a GlyphAgo Trial

MT Newswires Live

Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating Glyphagotm in Patients with Generalized Anxiety Disorder and Sleep Disturbance

THOMSON REUTERS

Seaport Therapeutics - Topline Data from Phase 2a Glyphago Trial Expected in Early 2028

THOMSON REUTERS

Seaport Therapeutics Initiated at Strong Buy by Raymond James

Seaport Therapeutics initiated with a Strong Buy at Raymond James

Seaport Therapeutics CEO Daphne Zohar Presents at Goldman Sachs Life Sciences Symposium

Citi Keeps Their Buy Rating on Seaport Therapeutics, Inc. (SPTX)

Seaport Therapeutics Price Target Maintained with a $50.00/Share by HC Wainwright & Co.

PureTech Says Seaport Therapeutics Reports Positive Phase 1 Driving Trial Results for GlyphAllo

PureTech Health: Glyphallo 375 Mg Did not Impair Next-Morning Driving Performance on Day 5

THOMSON REUTERS

PureTech Health: Glyphallo was Well-Tolerated, with no Serious Adverse Events Reported

THOMSON REUTERS

PureTech Health: to Submit Glyphallo Phase 1 Results to U.S. FDA

THOMSON REUTERS

Sector Update: Healthcare Stocks Mixed Premarket Wednesday

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/SPTX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"SPTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SPTX\",,,,,undefined,":{"symbol":"SPTX","market":"US","secType":"STK","nameCN":"Seaport Therapeutics","latestPrice":18.15,"timestamp":1791576000000,"preClose":17.91,"halted":0,"volume":171206,"hourTrading":{"tag":"盘后","latestPrice":18.15,"preClose":18.15,"latestTime":"19:30 EDT","volume":219,"amount":3974.85,"timestamp":1791588604970,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.013400335008375123,"floatShares":14160000,"shares":53530550,"eps":-2.516,"marketStatus":"Post-Mkt","change":0.24,"latestTime":"10-09 19:38:25 EDT","open":18,"high":18.79,"low":17.89,"amount":3113237.29696,"amplitude":0.050251,"askPrice":21.48,"askSize":160,"bidPrice":17.63,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-2.516,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1791590400000},"marketStatusCode":4,"adr":0,"listingDate":1777608000000,"exchange":"NASDAQ","adjPreClose":17.91,"postHourTrading":{"tag":"盘后","latestPrice":18.15,"preClose":18.15,"latestTime":"19:30 EDT","volume":219,"amount":3974.85,"timestamp":1791588604970,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.777536},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SPTX\",,,,,undefined,":{"symbol":"SPTX","floatShares":14160000,"roa":"-18.90%","roe":"-28.08%","lyrEps":-10.043037,"volumeRatio":0.777536,"shares":53530550,"dividePrice":0,"high":18.79,"amplitude":0.050251,"preClose":17.91,"low":17.89,"week52Low":14.85,"pbRate":"2.30","week52High":28.3833,"institutionHeld":0,"latestPrice":18.15,"committee":-0.987578,"eps":-2.516,"divideRate":0,"volume":171206,"delay":0,"ttmEps":-2.516,"open":18,"prevYearClose":18,"prevWeekClose":18.42,"prevMonthClose":20.17,"prevQuarterClose":20.17,"fiveDayClose":18.42,"twentyDayClose":23.34,"sixtyDayClose":19.52},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SPTX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-03","symbol":"SPTX","fiscalQuarterEnding":"2026/06","expectedEps":-0.71,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1785729600000,"reportTimeType":"pre","actualEps":-1.78}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SPTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SPTX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.375,"hold":0.125,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.375,"analysts":8,"updateTime":1790395200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SPTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SPTX","date":"2026-10-08","current":-7.213831,"percent":0.990741,"low":-14.505892,"twenty":-12.644435,"median":-11.330579,"eighty":-9.343911,"high":-6.903604,"avg":-11.032351,"sd":1.844446,"marketCap":959802761},"quantilePoints":[{"date":"2026-05-08","current":-10.976498,"twenty":-12.440976,"median":-11.330579,"eighty":-11.259763,"marketCap":821931163},{"date":"2026-05-15","current":-11.99625,"twenty":-12.004748,"median":-11.348283,"eighty":-11.231436,"marketCap":898291219},{"date":"2026-05-22","current":-12.173291,"twenty":-12.004748,"median":-11.330579,"eighty":-11.135126,"marketCap":911548174},{"date":"2026-05-29","current":-13.31343,"twenty":-12.537286,"median":-11.684659,"eighty":-11.163453,"marketCap":996922959},{"date":"2026-06-05","current":-12.661922,"twenty":-12.698746,"median":-12.017495,"eighty":-11.247016,"marketCap":948137367},{"date":"2026-06-12","current":-12.548616,"twenty":-12.593938,"median":-12.03874,"eighty":-11.316416,"marketCap":939652917},{"date":"2026-06-18","current":-10.501726,"twenty":-12.6166,"median":-12.03874,"eighty":-11.222938,"marketCap":915372405},{"date":"2026-06-26","current":-11.889673,"twenty":-12.53162,"median":-11.895161,"eighty":-11.165224,"marketCap":1036351448},{"date":"2026-07-02","current":-13.173217,"twenty":-12.752567,"median":-12.017495,"eighty":-11.198861,"marketCap":1148230297},{"date":"2026-07-10","current":-12.595929,"twenty":-12.752567,"median":-12.03874,"eighty":-11.215593,"marketCap":1097911580},{"date":"2026-07-17","current":-11.987935,"twenty":-12.752567,"median":-12.12726,"eighty":-11.302253,"marketCap":1044916336},{"date":"2026-07-24","current":-13.474144,"twenty":-12.866109,"median":-12.187454,"eighty":-11.330579,"marketCap":1174460267},{"date":"2026-07-31","current":-12.479243,"twenty":-12.804736,"median":-12.201617,"eighty":-11.330579,"marketCap":1087740776},{"date":"2026-08-07","current":-14.1804,"twenty":-12.896856,"median":-12.347233,"eighty":-11.365987,"marketCap":1236020399},{"date":"2026-08-14","current":-9.423399,"twenty":-12.896856,"median":-12.221306,"eighty":-11.295171,"marketCap":1269209340},{"date":"2026-08-21","current":-9.552568,"twenty":-12.881452,"median":-12.180373,"eighty":-11.146457,"marketCap":1286606769},{"date":"2026-08-28","current":-10.432907,"twenty":-12.804736,"median":-12.123719,"eighty":-11.036024,"marketCap":1405176937},{"date":"2026-09-04","current":-9.653917,"twenty":-12.782309,"median":-12.017495,"eighty":-10.432907,"marketCap":1300257059},{"date":"2026-09-11","current":-9.252498,"twenty":-12.759648,"median":-11.944292,"eighty":-9.835946,"marketCap":1246191204},{"date":"2026-09-18","current":-8.67223,"twenty":-12.748317,"median":-11.889673,"eighty":-9.660275,"marketCap":1168036601},{"date":"2026-09-25","current":-8.394019,"twenty":-12.694907,"median":-11.667409,"eighty":-9.560914,"marketCap":1130565216},{"date":"2026-10-02","current":-7.531565,"twenty":-12.665919,"median":-11.472211,"eighty":-9.452015,"marketCap":1014403922},{"date":"2026-10-08","current":-7.126172,"twenty":-12.644435,"median":-11.330579,"eighty":-9.343911,"marketCap":959802761}],"updateTime":1791589105659},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SPTX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2674865001","title":"PureTech-Founded Seaport Therapeutics Unveils Strong Phase 1 Data for GlyphAgo","url":"https://stock-news.laohu8.com/highlight/detail?id=2674865001","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674865001?lang=en_us&edition=fundamental","pubTime":"2026-10-10 01:02","pubTimestamp":1791565369,"startTime":"0","endTime":"0","summary":"PureTech Health ( ($GB:PRTC) ) just unveiled an update. PureTech’s founded entity Seaport Therapeutics has presented detailed Phase 1 pharmacokinet...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/puretech-founded-seaport-therapeutics-unveils-strong-phase-1-data-for-glyphago?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/puretech-founded-seaport-therapeutics-unveils-strong-phase-1-data-for-glyphago?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","SPTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674851885","title":"Seaport Therapeutics Says Drug Potentially Reduces Liver Impact of Depression Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2674851885","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674851885?lang=en_us&edition=fundamental","pubTime":"2026-10-09 20:01","pubTimestamp":1791547266,"startTime":"0","endTime":"0","summary":"Seaport Therapeutics'  GlyphAgo showed a \"statistically significant\" 6.8-fold increase in bioavailability of the antidepressant agomelatine compared with unmodified agomelatine in a 174-patient phase 1 clinical trial, the company said Friday.GlyphAgo, designed to enhance lymphatic absorption of agomelatine, also achieved \"therapeutically relevant\" exposure of agomelatine at substantially lower doses meant to reduce liver damage, the company said.The drug also potentially reduces the risk of liver damage and the need for routine liver monitoring that has curtailed agomelatine's use to treat severe depression.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","SPTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674784856","title":"Seaport Therapeutics presents additional PK data from Phase 1 GlyphAgo trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2674784856","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674784856?lang=en_us&edition=fundamental","pubTime":"2026-10-09 19:05","pubTimestamp":1791543929,"startTime":"0","endTime":"0","summary":"Seaport Therapeutics (SPTX) announced the presentation of Phase 1 clinical data for GlyphAgo at the 39th European College of Neuropsychopharmacolog...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/seaport-therapeutics-presents-additional-pk-data-from-phase-1-glyphago-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/seaport-therapeutics-presents-additional-pk-data-from-phase-1-glyphago-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","SPTX","EPV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674856867","title":"Seaport Therapeutics Presents Phase 1 GlyphAgo Data Showing 6.8-Fold Increase in Agomelatine Bioavailability","url":"https://stock-news.laohu8.com/highlight/detail?id=2674856867","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674856867?lang=en_us&edition=fundamental","pubTime":"2026-10-09 19:00","pubTimestamp":1791543643,"startTime":"0","endTime":"0","summary":"Seaport Therapeutics presents Phase 1 GlyphAgo data showing 6.8-fold increase in agomelatine bioavailabilitySeaport Therapeutics disclosed additional Phase 1 pharmacokinetic data for GlyphAgo ahead of","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261009:nNDLc2RVJ5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SPTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674000855","title":"Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of Glyphago™ at the 39TH European College of Neuropsychopharmacology (Ecnp) Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2674000855","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674000855?lang=en_us&edition=fundamental","pubTime":"2026-10-09 19:00","pubTimestamp":1791543600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261009:nTUABNSXLQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","SPTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673076244","title":"Seaport Therapeutics Price Target Maintained with a $50.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2673076244","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673076244?lang=en_us&edition=fundamental","pubTime":"2026-10-08 18:45","pubTimestamp":1791456300,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SPTX/analyst-ratings","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673001491","title":"PureTech-Founded Seaport Therapeutics Doses First Patient in Mid-Stage GAD Trial of GlyphAgo","url":"https://stock-news.laohu8.com/highlight/detail?id=2673001491","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673001491?lang=en_us&edition=fundamental","pubTime":"2026-10-08 01:02","pubTimestamp":1791392546,"startTime":"0","endTime":"0","summary":"An announcement from PureTech Health ( ($GB:PRTC) ) is now available. PureTech-founded Seaport Therapeutics has advanced its neuropsychiatric pipel...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/puretech-founded-seaport-therapeutics-doses-first-patient-in-mid-stage-gad-trial-of-glyphago?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/puretech-founded-seaport-therapeutics-doses-first-patient-in-mid-stage-gad-trial-of-glyphago?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","SPTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673972340","title":"Seaport Therapeutics Doses First Patient in Phase 2a GlyphAgo Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2673972340","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673972340?lang=en_us&edition=fundamental","pubTime":"2026-10-07 19:27","pubTimestamp":1791372467,"startTime":"0","endTime":"0","summary":"Seaport Therapeutics (SPTX) said Wednesday that the first patient has been dosed in a phase 2a clinical trial evaluating GlyphAgo in adults with generalized anxiety disorder and sleep disturbance.The ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SPTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673209205","title":"Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating Glyphagotm in Patients with Generalized Anxiety Disorder and Sleep Disturbance","url":"https://stock-news.laohu8.com/highlight/detail?id=2673209205","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673209205?lang=en_us&edition=fundamental","pubTime":"2026-10-07 19:00","pubTimestamp":1791370800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261007:nTUA8X47GF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673092051","title":"Seaport Therapeutics - Topline Data from Phase 2a Glyphago Trial Expected in Early 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2673092051","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673092051?lang=en_us&edition=fundamental","pubTime":"2026-10-07 19:00","pubTimestamp":1791370800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261007:nTUA8X47GF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","SPTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670442401","title":"Seaport Therapeutics Initiated at Strong Buy by Raymond James","url":"https://stock-news.laohu8.com/highlight/detail?id=2670442401","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670442401?lang=en_us&edition=fundamental","pubTime":"2026-09-25 19:33","pubTimestamp":1790335980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SPTX/analyst-ratings","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1363072403.SGD","RJF","IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4588","BK4585","LU0971096721.USD","BK4007","LU2265009873.SGD","LU1804176565.USD","SPTX","BK4127","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670444852","title":"Seaport Therapeutics initiated with a Strong Buy at Raymond James","url":"https://stock-news.laohu8.com/highlight/detail?id=2670444852","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670444852?lang=en_us&edition=fundamental","pubTime":"2026-09-25 18:15","pubTimestamp":1790331322,"startTime":"0","endTime":"0","summary":"Raymond James analyst Tiago Fauth initiated coverage of Seaport Therapeutics (SPTX) with a Strong Buy rating and $46 price target The firm sees a m...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/seaport-therapeutics-initiated-with-a-strong-buy-at-raymond-james-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/seaport-therapeutics-initiated-with-a-strong-buy-at-raymond-james-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4127","LU1363072403.SGD","BK4585","LU2265009873.SGD","IE00B64PRP62.GBP","LU1804176565.USD","IE00B3QW5Z07.USD","LU0971096721.USD","IE00BGHQF748.EUR","BK4588","SPTX","BK4007","RJF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667265005","title":"Seaport Therapeutics CEO Daphne Zohar Presents at Goldman Sachs Life Sciences Symposium","url":"https://stock-news.laohu8.com/highlight/detail?id=2667265005","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667265005?lang=en_us&edition=fundamental","pubTime":"2026-09-14 19:01","pubTimestamp":1789383664,"startTime":"0","endTime":"0","summary":"Seaport Therapeutics CEO Daphne Zohar presents at Goldman Sachs Life Sciences SymposiumSeaport Therapeutics management is scheduled for investor meetings at the H.C. Wainwright Global Investment Confe","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nNDL6g4wDs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSX","LU1868837136.USD","LU0210536198.USD","IE00BFXG1179.USD","IE0002270589.USD","BK4504","LU2750360641.GBP","LU2237443978.SGD","LU2471134879.HKD","LU2237443382.USD","SPTX","LU0251131958.USD","IE0034235188.USD","LU1868836914.USD","LU0742534661.SGD","BK4516","LU2237443895.HKD","BK4533","LU0868494617.USD","LU2471134796.USD","LU0942090050.USD","IE0004086264.USD","BK4007","BK4550","IE00BSNM7G36.USD","LU0345770308.USD","LU1868836591.USD","LU0106831901.USD","LU2265009873.SGD","IE00B19Z3581.USD","LU1868837300.USD","LU1868836757.USD","LU2237443465.HKD","LU1894683264.USD","LU1144417596.USD","LU1668664300.SGD","LU1804176565.USD","LU0048573561.USD","LU2750360997.AUD","BK4585","LU2471134523.USD","LU0868494708.USD","LU2237443622.USD","LU0251142724.SGD","IE00B19Z3B42.SGD","LU1894683348.USD","BK4552","LU2237438978.USD","IE0004091025.USD","LU2896262040.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666631599","title":"Citi Keeps Their Buy Rating on Seaport Therapeutics, Inc. (SPTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2666631599","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666631599?lang=en_us&edition=fundamental","pubTime":"2026-09-10 21:35","pubTimestamp":1789047319,"startTime":"0","endTime":"0","summary":"Citi analyst Yigal Nochomovitz maintained a Buy rating on Seaport Therapeutics, Inc. today and set a price target of $35.00. Nochomovitz covers the...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/citi-keeps-their-buy-rating-on-seaport-therapeutics-inc-sptx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/citi-keeps-their-buy-rating-on-seaport-therapeutics-inc-sptx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SPTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666567255","title":"Seaport Therapeutics Price Target Maintained with a $50.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2666567255","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666567255?lang=en_us&edition=fundamental","pubTime":"2026-09-10 18:53","pubTimestamp":1789037580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SPTX/analyst-ratings","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666953424","title":"PureTech Says Seaport Therapeutics Reports Positive Phase 1 Driving Trial Results for GlyphAllo","url":"https://stock-news.laohu8.com/highlight/detail?id=2666953424","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666953424?lang=en_us&edition=fundamental","pubTime":"2026-09-10 01:18","pubTimestamp":1788974333,"startTime":"0","endTime":"0","summary":"BRIEF-PureTech Says Seaport Therapeutics Reports Positive Phase 1 Driving Trial Results for GlyphAlloSept 9 (Reuters)-PureTech Health PLCPRTC.L:PURETECH FOUNDED ENTITY SEAPORT THERAPEUTICS REPORTS POS","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nTUA62HR5N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPTX","BK4007","BK5083","PRTC.UK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666534453","title":"PureTech Health: Glyphallo 375 Mg Did not Impair Next-Morning Driving Performance on Day 5","url":"https://stock-news.laohu8.com/highlight/detail?id=2666534453","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666534453?lang=en_us&edition=fundamental","pubTime":"2026-09-10 01:14","pubTimestamp":1788974040,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nTUA62HR5N:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK5083","PRTC.UK","BK4007","SPTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666534285","title":"PureTech Health: Glyphallo was Well-Tolerated, with no Serious Adverse Events Reported","url":"https://stock-news.laohu8.com/highlight/detail?id=2666534285","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666534285?lang=en_us&edition=fundamental","pubTime":"2026-09-10 01:14","pubTimestamp":1788974040,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nTUA62HR5N:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK5083","PRTC.UK","BK4007","SPTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666498534","title":"PureTech Health: to Submit Glyphallo Phase 1 Results to U.S. FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2666498534","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666498534?lang=en_us&edition=fundamental","pubTime":"2026-09-10 01:14","pubTimestamp":1788974040,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nTUA62HR5N:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPTX","BK4007","PRTC.UK","BK5083"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666351825","title":"Sector Update: Healthcare Stocks Mixed Premarket Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2666351825","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666351825?lang=en_us&edition=fundamental","pubTime":"2026-09-09 21:16","pubTimestamp":1788959818,"startTime":"0","endTime":"0","summary":"Healthcare stocks were mixed premarket Wednesday, with the State Street Health Care Select Sector SPDR ETF  0.4% higher and the iShares Biotechnology ETF  down 0.3%.InnovAge Holding  shares were up more than 10% after the company reported that it swung to earnings in fiscal Q4 amid stronger-than-expected sales growth.Seaport Therapeutics  stock was nearly 4% higher after the company said its phase 1 driving simulation trial of GlyphAllo met its primary endpoint, with the 375 mg dose showing no next-morning driving impairment versus placebo after multiple-day dosing.Evommune's  phase 2b trial of EVO756 to treat adults with moderate-to-severe atopic dermatitis didn't meet its primary and secondary endpoints in any of the doses studied, the company said. Evommune shares were down more than 8% pre-bell.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SPTX","BK4196","XLV","IBB","EVMN","HCSG","BK4007","LABU","XBI","BK4585","LU0128526141.USD","INNV","BK4139","BK4137","BK4588","BK4581","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":73,"code":"91000000","status":"200"}]}}